The anomalous pharmacology of fentanyl

Eamonn Kelly, Katy Sutcliffe, Damiana Cavallo, Nokomis Ramos-Gonzalez, Norah Alhosan, Graeme Henderson

Research output: Contribution to journalReview article (Academic Journal)peer-review

51 Citations (Scopus)

Abstract

Fentanyl is a key therapeutic used in anaesthesia and pain management. It is also increasingly used illicitly and is responsible for a large and growing number of opioid overdose deaths, especially in North America. A number of factors have been suggested to contribute to fentanyl's lethality, including rapid onset of action, in vivo potency, ligand bias, induction of muscle rigidity and reduced sensitivity to reversal by naloxone. Some of these factors can be considered to represent "anomalous" pharmacological properties of fentanyl when compared to prototypical opioid agonists such as morphine. In this review, we examine the nature of fentanyl's "anomalous" properties, to determine whether there really is a pharmacological basis to support the existence of such properties, and also discuss whether such properties are likely to contribute to overdose deaths involving fentanyls.

Original languageEnglish
JournalBritish Journal of Pharmacology
Early online date2 Jul 2021
DOIs
Publication statusPublished - 2022

Bibliographical note

Funding Information:
This study was supported by UKRI Medical Research Council (MRC) grant (MR/S010890/1) as well as UKRI Biotechnology and Biological Sciences Research Council (BBSRC) studentships awarded to K.S. and N.R.‐G. under the South West Biosciences (SWBio) DTP scheme (Grant BB/J014400/1).

Publisher Copyright:
© 2021 The British Pharmacological Society

Fingerprint

Dive into the research topics of 'The anomalous pharmacology of fentanyl'. Together they form a unique fingerprint.

Cite this